Rosuvastatin Dosing in End-Stage Renal Disease Patients on Hemodialysis

Dosing Recommendations

• The Kidney Disease Outcomes Quality Initiative (KDOQI) recommends initiating rosuvastatin at 5 mg daily and not exceeding 10 mg daily in patients with creatinine clearance <30 mL/min/1.73 m² not on hemodialysis, with similar considerations for those on hemodialysis 1, 2

Pharmacokinetic and Clinical Considerations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that rosuvastatin has reduced renal excretion in patients with eGFR <60 mL/min/1.73 m², supporting the recommendation to avoid high-intensity dosing in CKD patients 3
• The AURORA trial found no significant benefit in cardiovascular outcomes with rosuvastatin 10 mg daily in hemodialysis patients compared to placebo, leading to recommendations for cautious use 4

Guideline Recommendations

• The KDIGO lipid management guidelines recommend against initiating statin therapy in patients already on dialysis but suggest continuing therapy if already established 3, 5
• The American College of Cardiology and other societies support the use of rosuvastatin with careful dose consideration in patients with renal impairment, emphasizing the importance of not exceeding the 10 mg daily dose in ESRD patients on hemodialysis 4, 5

Rosuvastatin Dosing Considerations in Renal Impairment

Standard Dosing by Renal Function

• For patients with severe renal impairment, initiate rosuvastatin at 5 mg once daily and do not exceed 10 mg daily, as recommended by the American Journal of Kidney Diseases guidelines 6
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines are not explicitly mentioned for this fact, however, the dosing applies to patients not on hemodialysis 6

Intensity Selection in CKD

• Moderate-intensity rosuvastatin (5-10 mg) lowers LDL-C by 30-50%, according to the American Diabetes Association, as published in Diabetes Care 7
• High-intensity rosuvastatin (20-40 mg) lowers LDL-C by ≥50%, as per the American Diabetes Association, published in Diabetes Care 7

Common Pitfalls to Avoid

• Do not use high-intensity doses (20-40 mg) in severe renal impairment, as this increases risk of myopathy and other adverse effects, as noted in the American Journal of Kidney Diseases 6